Maybe the generics launch on a small scale but it won't be meaningful in terms of derailing AMRN in USA market. Also, generics won't be able to get significant economies of scale from whatever they produce. The generics have to be so circumspect going forward as a result of the Teva ruling. It's a game changer.
The lost profits / damages here are huge.
Oh the irony: we needed a speedy resolution to our case at one point and now it's the generics who need a speedy resolution. Unfortunately cases move through the court system at a slow pace. GSK v. Teva was argued last September 2019 and the ruling came out a year later. Good luck with en banc that will take more time and then an eventual appeal to Supreme Court....we are talking years. LOL
Tick tock tick tock......Amarin will benefit from more delays.
Pauline Newman delivered in a major way for AMRN shareholders.
News 
Market Data 
Discover 
AI
